198 related articles for article (PubMed ID: 35668669)
1. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
3. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
5. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
6.
Wang L; Zhang Z; Merkens H; Zeisler J; Zhang C; Roxin A; Tan R; Bénard F; Lin KS
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744904
[TBL] [Abstract][Full Text] [Related]
7. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years.
Dalm S; Duan H; Iagaru A
PET Clin; 2024 Jul; 19(3):401-415. PubMed ID: 38644111
[TBL] [Abstract][Full Text] [Related]
8. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
9. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.
Ananias HJ; de Jong IJ; Dierckx RA; van de Wiele C; Helfrich W; Elsinga PH
Curr Pharm Des; 2008; 14(28):3033-47. PubMed ID: 18991717
[TBL] [Abstract][Full Text] [Related]
10. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.
Baratto L; Jadvar H; Iagaru A
Mol Imaging Biol; 2018 Aug; 20(4):501-509. PubMed ID: 29256046
[TBL] [Abstract][Full Text] [Related]
12. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
13. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
14. A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor-Positive Prostate Cancer.
Bratanovic IJ; Zhang C; Zhang Z; Kuo HT; Colpo N; Zeisler J; Merkens H; Uribe C; Lin KS; Bénard F
J Nucl Med; 2022 Mar; 63(3):424-430. PubMed ID: 34301778
[TBL] [Abstract][Full Text] [Related]
15. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.
Chatalic KL; Konijnenberg M; Nonnekens J; de Blois E; Hoeben S; de Ridder C; Brunel L; Fehrentz JA; Martinez J; van Gent DC; Nock BA; Maina T; van Weerden WM; de Jong M
Theranostics; 2016; 6(1):104-17. PubMed ID: 26722377
[TBL] [Abstract][Full Text] [Related]
17. An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting.
Yu Z; Ananias HJ; Carlucci G; Hoving HD; Helfrich W; Dierckx RA; Wang F; de Jong IJ; Elsinga PH
Curr Pharm Des; 2013; 19(18):3329-41. PubMed ID: 23431995
[TBL] [Abstract][Full Text] [Related]
18. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
19. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
20. Comparison of biological properties of [
Rousseau E; Lau J; Zhang Z; Zhang C; Kwon D; Uribe CF; Kuo HT; Zeisler J; Bratanovic I; Lin KS; Bénard F
J Labelled Comp Radiopharm; 2020 Feb; 63(2):56-64. PubMed ID: 31715025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
